Ustekinumab biosimilar (Alvotech)

乌司奴单抗生物类似药 (Alvotech)

Report date: 2024/10/23 14:18:40

Base Information

Drug NameUstekinumab biosimilar (Alvotech)
Drug Alias Nameustekinumab-aeknJamtekiUzpruvoSELARSDI™JamtekiTM +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-12Interleukin-23Interleukin-12 subunit beta
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2023/09/25
Country/TerritoryCanadaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvotech hf
China Registration ClassN/A

Develop Information

Active CompaniesMedImpact Holdings IncLumicera Health Services LLCAlvotech USA Inc +[6] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A